rituximab
Sign in to saveAlso known as Ig gamma-1 chain C region, Rituxan, Mabthera
Rituximab, sold under the brand name Rituxan among others, is a monoclonal antibody medication used to treat certain autoimmune diseases and types of cancer. It is used for non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis, idiopathic thrombocytopenic purpura, pemphigus vulgaris, myasthenia gravis and Epstein–Barr virus-positive mucocutaneous ulcers. It is given by slow intravenous infusion.
Key facts
- Drug.CAS_number
- 174722-31-7
- Drug.Verifiedfields
- changed
- Drug.verifiedrevid
- 458438457
- Drug.image
- Rituximab.png
- Drug.width
- 300
- Drug.type
- mab
- Drug.mab_type
- mab
- Drug.source
- xi/o
- Drug.target
- CD20
- Drug.tradename
- Rituxan, Mabthera, others
- Drug.MedlinePlus
- a607038
- Drug.DailyMedID
- Rituximab
- Drug.pregnancy_AU
- C
- Drug.routes_of_administration
- Intravenous
- Drug.class
- Monoclonal antibody
- Drug.ATC_prefix
- L01
- Drug.ATC_suffix
- FA01
- Drug.biosimilars
- rituximab-abbs, rituximab-pvvr, rituximab-arrx, Blitzima Ituxredi, Riabni, Rixathon, Riximyo, Ruxience, Truxima
via Wikipedia infobox
Research
37,515 papers- A tale of two antibodies: obinutuzumab versus rituximab.British journal of haematology · 2018
- Rituximab in Subepidermal Blistering Diseases.Dermatology (Basel, Switzerland) · 2023
- Systematic Review of Safety and Efficacy of Rituximab in Treating Immune-Mediated Disorders.Frontiers in immunology · 2019
- Rituximab for myasthenia gravis.The Cochrane database of systematic reviews · 2025
- Rituximab resistance in ITP and beyond.Frontiers in immunology · 2023
via PubMed
~11 min read
Encyclopedic overview
18 sectionsContents
- Medical uses
- Blood cancers
- Autoimmune diseases
- Adverse events
- Mechanisms of action
- History
- Society and culture
- Legal status
- Biosimilars
- Economics
- Tailored-dosing
- Research
- Myalgic encephalomyelitis/chronic fatigue syndrome
- Intrathecal
- Other anti-CD20 monoclonals
- References
- Further reading
- External links
Rituximab, sold under the brand name Rituxan among others, is a monoclonal antibody medication used to treat certain autoimmune diseases and types of cancer. It is used for non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis, idiopathic thrombocytopenic purpura, pemphigus vulgaris, myasthenia gravis and Epstein–Barr virus-positive mucocutaneous ulcers. It is given by slow intravenous infusion.
The most common side effects with intravenous infusions are reactions related to the infusion (such as fever, chills and shivering) while most common serious side effects are infusion reactions, infections and heart-related problems. Similar side effects are seen when it is injected under the skin, with the exception of reactions around the injections site (pain, swelling and rash), which occur more frequently with the skin injections.
Excerpted from Wikipedia’s “rituximab” article, available under the CC BY-SA 4.0 licence.